These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1722796)

  • 1. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
    el Etreby MF; Nishino Y; Habenicht UF; Henderson D
    J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
    el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The function and the role of aromatase inhibitors in the treatment of BPH.
    el Etreby MF; Habenicht UF
    Prog Clin Biol Res; 1994; 386():209-30. PubMed ID: 7528389
    [No Abstract]   [Full Text] [Related]  

  • 5. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
    Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
    Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of estrogen deprivation on human benign prostatic hyperplasia.
    Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
    Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF
    Prostate; 1986; 8(2):181-94. PubMed ID: 2419882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
    Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione.
    Habenicht UF; Schwarz K; Neumann F; el Etreby MF
    Prostate; 1987; 11(4):313-26. PubMed ID: 2446299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.
    Trachtenberg J; Hicks LL; Walsh PC
    J Clin Invest; 1980 May; 65(5):1051-9. PubMed ID: 6154062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
    Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
    Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of metachromasia in experimentally induced hyperplastic/hypertrophic changes in the prostate of the cynomolgus monkey (Macaca fascicularis).
    Habenicht UF; el Etreby MF; Lewis R; Ghoniem G; Roberts J
    J Urol; 1989 Dec; 142(6):1624-6. PubMed ID: 2479780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings.
    Suzuki K; Ito K; Tamura Y; Suzuki T; Honma S; Yamanaka H
    Prostate; 1996 May; 28(5):328-37. PubMed ID: 8610061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
    Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
    Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism.
    Brodie AM; Son C; King DA; Meyer KM; Inkster SE
    Cancer Res; 1989 Dec; 49(23):6551-5. PubMed ID: 2479464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunolocalization of androgen receptors, estrogen alpha receptors, and estrogen beta receptors in experimentally induced canine prostatic hyperplasia.
    Gallardo F; Lloreta J; García F; Moll X; Baró T; González LA; Morote J; Reventos J; Mogas T
    J Androl; 2009; 30(3):240-7. PubMed ID: 19136389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.